Lack of Effect of Pioglitazone on Postprandial Triglyceride Levels in Type 2 Diabetes
- Dai Shimono, MD,
- Naomitsu Kuwamura, MD,
- Yoshio Nakamura, MD and
- Hiroyuki Koshiyama, MD
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo, Japan
We read with interest an article by Aronoff et al. (1), which indicated that monotherapy of pioglitazone, a peroxisome proliferator–activated receptor (PPAR)-γ agonist, can improve lipid profile as well as glycemic control in type 2 diabetes. However, because they evaluated dyslipidemia in the fasted state, as most investigators do, it remains unknown whether pioglitazone may ameliorate postprandial dyslipidemia, which has recently been suggested to be an independent risk factor of atherosclerosis (456). We have previously indicated that troglitazone, another PPAR-γ agonist, can cause a decrease in postprandial triglyceride levels …
